Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTAIN: Certolizumab Pegol in RA
NCT00674362Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2008
- Primary completion
- May 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 5
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Jun 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00674362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00674362.